Introduction: Various glucocorticoid regimens have been used in the treatment of patients with adrenal insufficiency, yet the differences between such regimens on health outcomes are unclear.
Introduction:
Adrenal insufficiency is a life threatening condition that warrants prompt recognition and treatment. Patients with primary and secondary chronic adrenal insufficiency generally require lifelong treatment with glucocorticoids (1), but despite such therapy, continue to have higher morbidity and mortality rates (2, 3) . Adrenal insufficiency is also associated with impaired subjective health status in patients considered to be receiving "adequate" hormone replacement with glucocorticoids (1, 4, 5) .
Many different forms of glucocorticoids are available and have been used in the management of adrenal insufficiency. Short acting preparations which are easy to titrate and with a relatively low cost, such as hydrocortisone and cortisone acetate, are the currently preferred methods of glucocorticoid replacement (6, 7) . Nevertheless, individualizing a glucocorticoid regimen in a way that assures optimal quality of life while minimizing glucocorticoid-induced side effects, remains challenging (8) . Recently, efforts have been made to develop preparations that more closely mimic physiological circadian cortisol rhythm (9, 10) .
In this systematic review and meta-analysis, we aimed to study the effects of different glucocorticoid regimens in patients with adrenal insufficiency on various patient-important outcomes (11) , including quality of life, bone health, incidence of adrenal crisis and death. In DOI:10.4158/EP161428.OR © 2016 AACE. pediatric studies, we planned to evaluate final adult height. The main objective of this systematic review was to guide practitioners in choosing an appropriate glucocorticoid regimen when managing patients with adrenal insufficiency.
Methods:
This study was performed based on a protocol that was designed in advance. The report of the this study complies with the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) (12) .
Inclusion and exclusion criteria:
The inclusion criteria were specified in the predefined protocol to include original prospective and retrospective comparative and non-comparative studies that enrolled adults or children with adrenal insufficiency and evaluated the outcomes of interest. We included studies regardless of their publication status or language. We excluded all non-original studies including case reports and review articles. Studies involving children with congenital adrenal hyperplasia were excluded, as supraphysiological doses of glucocorticoids are commonly used to suppress ACTH secretion in those patients.
Outcomes of interest were quality of life, bone mineral density (BMD) and fractures, number of adrenal crises, final adult height in children with adrenal insufficiency, and mortality.
Data source and search strategy:
DOI:10.4158/EP161428.OR © 2016 AACE.
We conducted a comprehensive multi language search of several databases from their earliest inception to July 2016. The databases included Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced Mayo Clinic librarian (LP) with input from the study's principle investigator (AA). Controlled vocabulary supplemented with keywords was used in the search (see appendix 1 for details of the search strategy). We performed google search for any additional studies that could have been missed using the electronic search. We also searched previously published reviews and cross referenced the cited studies with the abstracts we identified in our search and contacted content experts for additional references.
Study identification and data extraction:
Reviewers worked independently and in pairs to review the titles and abstracts identified in the original search. Disagreements between the reviewers led to including the abstract to the next level of screening. Full texts of the eligible abstracts were retrieved for full text screening. Again, reviewers worked independently and in pairs to review the articles. Disagreements between the reviewers were solved in consensus.
Data were then extracted in duplicate using a web based form. Information extracted from each article included: first author's name and year of publication; inclusion and exclusion criteria; type of adrenal insufficiency; number of patients included; follow up duration; comorbidities; and types, dose and frequency of glucocorticoids used. For quality of life studies, we extracted the type of questionnaire used and patients' scores before and after treatment. Further data was extracted from these questionnaires for all the domains, but with concentration on the physical and mental domains in the meta-analysis. For bone mineral density, we extracted the reported DOI:10.4158/EP161428.OR © 2016 AACE.
T-and Z-scores before and after treatment with glucocorticoids, and the site where the bone mineral density was measured. For the final adult height outcome, we aimed to extract data for the accumulated dose of glucocorticoids used in children with adrenal insufficiency and their final adult height data compared to their predicted final adult height for their families. The number of incidents in each group and measures of association were extracted from the studies that reported number of adrenal crises or mortality rates. The hydrocortisone equivalent dose was calculated based on the following formulas; 1 mg of dexamethasone = 25 mg of hydrocortisone. 1 mg of prednisone = 4 mg of hydrocortisone.
Reviewers, in duplicate, determined the methodological quality of studies and collected all the descriptive, methodological and outcome data. We attempted to contact authors of the original studies by email for missing data.
Risk of bias assessment:
The risk of bias was assessed using the Cochrane tool for Randomized control trials (13) and the Newcastle Ottawa scale for observational studies (14) .
Statistical analysis:
Patients' scores from different quality of life questionnaires were standardized and expressed in standardized mean differences (SMD) using Cohen's d (15) and then combined using the profile likelihood random-effects (16, 17) model. Heterogeneity was measured using I 2 statistics. I 2 values of less than 25%, 25%-50%, and greater than 50% suggest low, moderate, and high heterogeneity, respectively (18) . A two sided p value of less than 0.05 was considered statistically significant. All statistical analyses were conducted using Stata version 14.0 When data were insufficient to perform statistical analysis, we reported the results narratively.
Results:
The search yielded 2947 abstracts. Thirty four studies and a total of 6719 patients with chronic adrenal insufficiency were finally included in this systematic review (Figure1).
Risk of bias assessment:
There was a medium to high risk of bias in the included randomized controlled trials (RCTs). Twenty two studies evaluated the effect of different glucocorticoid regimens on the quality of life of patients with adrenal insufficiency (one of them was an abstract) (20) ; of these, eight provided sufficient data for meta-analysis and included a total of 165 patients (119 with primary and 46 with secondary adrenal insufficiency). Five of these were cross-over randomized control trials.
Fourteen studies did not provide sufficient information for inclusion in the meta-analysis. These To analyze the effect of the total daily dose of hydrocortisone on quality of life in patients with adrenal insufficiency, we divided the dose regimens into "high" (hydrocortisone dose ≥ 30 mg/day or its dose equivalence) and "low" (hydrocortisone dose < 30 mg/day of hydrocortisone or its dose equivalence) glucocorticoid dose. The 30 mg cutoff was chosen because this arbitrarily separates patients in physiological versus supraphysiological total daily glucocorticoid replacement. We found no statistically significant difference between the effect of different total daily doses of hydrocortisone on quality of life in patients with adrenal insufficiency (p=0.15) ( Table 1) DOI:10.4158/EP161428.OR © 2016 AACE.
The effect of the different glucocorticoid regimens on quality of life was then examined. We found that patients receiving the extended release (ER) form of glucocorticoid were reported to have a higher quality of life score compared to the daily, twice daily and thrice daily regimens (p=0.01). However, only one of the studies included in the meta-analysis evaluated the effect of the extended release form. Similarly, dual release and continuous subcutaneous infusion forms of hydrocortisone showed superiority over conventional forms of glucocorticoids ( Figure 3 ). No statistically significant difference was found when comparison was made between the regimens of daily, twice daily and thrice daily dosing, (p=0.80) ( Figure 3 ).
Several additional studies (n=12) investigating the effect of total daily hydrocortisone dose on quality of life did not report an effect size and measure of dispersion; hence were not quantitatively combined in the meta-analysis. These studies only reported p values, results visually in graphs, correlation coefficients, mean z-scores; or did not report the exact number of patients or questionnaires scores. The findings of these studies are summarized in table 2. In brief, these studies reported similar results in that the use of dual release formulation was associated with higher quality of life (QoL) scores. Two studies demonstrated higher QoL scores with continuous subcutaneous hydrocortisone infusion compared to conventional therapy. Three studies (545 patients) reported lower QoL scores in patients who were over-treated with higher daily doses of hydrocortisone. However, two of these studies were cross sectional and one was an open label pre/post study, significantly limiting inference.
Bone mineral density
Eleven studies evaluated the effect of different glucocorticoid regimens on BMD in patients with adrenal insufficiency. (21-31) Of these, 5 were cohort studies, 4 were cross-sectional studies and two were case-control studies .
Studies that investigated the total daily glucocorticoid dose influence on BMD showed inconsistent results. Three studies reported a negative correlation and 3 studies found no correlation between the total daily hydrocortisone dose and BMD (though the studies showing no correlation reported only the p value without providing the correlation coefficient value).
Zelissen et al reported a negative correlation between BMD at the level of the lumbar spine and
the total daily hydrocortisone dose in men but not in women (27) . Koetz and Valero found that patients on hydrocortisone tend to have higher BMD when compared to patients receiving prednisone or prednisolone (24, 26) . Koetz, however, reported no difference in fracture rates between patients on hydrocortisone and patients on prednisolone.
Supplemental Table 2 summarizes the baseline characteristics of the included BMD studies.
Incidence of adrenal crises
Four studies evaluated the association between glucocorticoid replacement regimen and the incidence of adrenal crises. (21, (32) (33) (34) None of these studies found any direct correlation between the dose or type of glucocorticoid and occurrence of adrenal crisis. One of these studies found an increased rate of hospitalizations during the study period (12 years); they attributed that to possibly using lower doses of glucocorticoids compared to the past. (34) Supplemental table 2 summarizes the baseline characteristics of the included studies that assessed adrenal crisis.
Final adult height in children
We did not identify any study that evaluated the effect of glucocorticoid dose on final adult height (studies on patients with congenital adrenal hyperplasia were excluded).
Mortality
We did not identify any study that evaluated the effect of glucocorticoid dose on mortality.
Subgroup analysis:
We were not able to study the effect of different glucocorticoids regimens on primary vs. secondary adrenal insufficiency due to the small number of studies included in the metaanalysis and because most of these studies lumped all patients (with primary and secondary adrenal insufficiency) in their analysis
Discussion:
Patients treated for adrenal insufficiency continue to have impaired quality of life despite various available medical replacement modalities (4, 35) . Treatment with glucocorticoids aims to mimic the physiologic endogenous circadian secretion of cortisol in the body. However, variability of physiologic levels, both between individuals as well as intrinsic variability (such as circadian and stress-related), and the variability in glucocorticoid receptor sensitivity add to the challenge of optimally replacing glucocorticoids. In the absence of an adequate glucocorticoid replacement biomarker, clinicians have to rely on subjective criteria such as patients' sense of well-being and functional status and limited objective data such as weight, appetite and blood pressure, as well as clinical evidence of hypercortisolism (36) .
In the current systematic review and meta-analysis we attempted to examine the effect of total daily dose, frequency of dosing, and types of glucocorticoids on patient-important outcomes.
Low quality evidence suggests that higher QoL scores may be associated with using newer DOI:10.4158/EP161428.OR © 2016 AACE. modalities for glucocorticoid replacement including the dual release form of hydrocortisone, which had a good safety profile in one study (37) , the extended release form of prednisolone, and continuous hydrocortisone infusion. A recently published study (not reporting QoL outcomes) demonstrated that a dual release form of hydrocortisone was well tolerated and had good safety profile over 27 months of continuous treatment (37) . We also did not find a statistically significant difference in quality of life between patients receiving different total daily glucocorticoid doses (≥ 30 mg of hydrocortisone or equivalent vs. <30 mg); however, this conclusion was based on a small number of patients included in the metaanalysis (n= 165). We could not show a statistically significant difference in quality of life between patients receiving glucocorticoids once, twice or thrice daily.
Our study has several strengths and limitations. In terms of strengths, we conducted a comprehensive search of multiple databases by pairs of independent reviewers and did not restrict the inclusion criteria by language. We attempted to provide a quantitative comparison despite challenges of reporting, insufficient data and heterogeneity. The most significant limitation relates to the available evidence base. Most studies were uncontrolled or crosssectional, very small, or had short term follow up making inference about long-term effect quite limited. The studies used different questionnaires and instruments to assess QoL, which resulted in statistical heterogeneity. We were unable to combine some studies in quantitative analysis due to insufficient data; however, we appraised these studies individually and reported their findings, which were mostly consistent with the meta-analysis. We have attempted to exclude overlapping studies by comparing studies center, geographic location and years of enrollment. However, this remains a concern. DOI:10.4158/EP161428.OR © 2016 AACE.
The overall quality of evidence supporting the inferences provided here is low (38, 39) . Lastly, we were unable to analyze the various dosages of mineralocorticoid replacement or dehydroepiandrosterone sulfate (DHEAS) replacement that might have had some effects on the overall wellbeing in studies' participants.
While it is well known that chronic supraphysiologic doses of glucocorticoids have a negative impact on BMD, it is still unclear whether a correlation exists between the cumulative dose of glucocorticoids used to treat patients with chronic adrenal insufficiency and the change in BMD.
Data from available studies report inconsistent results ranging from no correlation between the cumulative daily dose of hydrocortisone and change in BMD, to a negative correlation. It should be noted that these were observational studies that included a small number of patients and most did not adjust for the patient's age and menopausal status. Therefore, long term randomized control trials are needed to better evaluate the effect of replacement doses of glucocorticoids on BMD in patients with adrenal insufficiency.
Adrenal crises may occur in patients despite receiving treatment for adrenal insufficiency. A retrospective study on 444 patients with adrenal insufficiency reported an incidence rate of 6.3 per 100 years (32) . We did not find an association between the total daily dose and frequency of adrenal crises. It is likely that factors other than the daily replacement dose play a role in adrenal crises prevention, such as patient education, adherence, knowledge of sick day rules, and availability of glucocorticoid injections. Three studies tried to identify the most likely risk frequency of adrenal crises, but did find that females and patients with diabetes insipidus were at increased risk for adrenal crises. Arlt et al reported a higher risk of adrenal crisis in females with autoimmune adrenalitis (35) .
Conclusion
The current available evidence is of low quality (comparison across studies, methodological limitations, substantial heterogeneity, and moderate risk of bias) and suggests that newer forms of glucocorticoids, including the dual release form of hydrocortisone, extended release form of prednisolone, and continuous subcutaneous infusion of hydrocortisone, may have a better effect on quality of life in patients with chronic adrenal insufficiency when compared to conventional forms of glucocorticoid therapy. It is important to note that most of this evidence is derived from double blinded randomized trials with short-term follow up, which makes interpreting QOL data more challenging; therefore randomized trials with longer follow up are needed to confirm the effect of newer modalities of treatment. No conclusive evidence of glucocorticoid dose correlation to quality of life could be drawn. Similarly, we were not able to demonstrate any relationship of glucocorticoid type and dose on detrimental effects on bone loss or rates of adrenal crisis. A large gap of knowledge exists regarding highly important outcomes such as mortality and height in children. Adults with complete adrenal insufficiency. All patients were treated with 3 different modes of cortisol replacement for 1 week each. The modes were: 20-X-10, 30-X-0, 0-X-30.
Cross over RCT
Ekman, 2012
To assess how equal dose of HC given 4 times a day/twice a day influence diurnal profiles of cortisol/ACTH and QOL
15
Adults with primary adrenal insufficiency. All patients were treated with 2 different modes of cortisol replacement for 4 weeks each: 20-X-10, 10-10-5-5.
Cross over RCT

Alonso, 2004(3)
To assess the effects of the traditional twice daily replacement dose of hydrocortisone vs thrice daily on clinical symptoms and HRQL
12
Patients with primary adrenal insufficiency who were evaluated in 2 separate occasions. First on their regular dose of 20-X-10 and then 3 months after switching to 10-5-5. 
Crosssectional
Gagliardi 2014 (18) to determine the effect of CSHI on SHS in AD. Prospective cohort * These studies did not provide sufficient effect size data to be included in meta-analysis and there results are reported narratively X-X refers to morning-night X-X-X refers to morning-afternoon-night X-X-X-X refers to dosing four times a day Supplemental Heureux, 2000 (23) To evaluate the severity and etiology of osteopenia in 24 patients with Addison's disease.
patients with
Addison's disease who are followed prospectively.
Cohort prospective
BMD
There was a significant correlation between the dose of hydrocortisone and BMD of the hip (r=-0.722). There was a significant correlation between the femoral BMD and hydrocortisone dose (r=-0.644).
the replacement dose of hydrocortisone is also higher among osteoporotic (23.9 + / -5. Zelissen, 1994 (28) To study the influence of glucocorticoid replacement therapy on bone mineral density.
patients with
Addison's disease who have been receiving therapy for a mean period of 10.6 years.
Cross sectional BMD
Men ( (29) To assess the bone density in patients with primary and secondary adrenocortical deficiency.
10 patients with primary adrenal insufficiency and 5 patients with secondary adrenal insufficiency. Mean duration of treatment was 104.8 months.
There was a significant negative correlation between lumbar spine BMD and hydrocortisone dose r=-0.526, P=0.04. Statistically significant correlation between lumbar spine BMD and cumulative dose of hydrocortisone r=-0.59, P=0.02. Braatvedt, 1999 (30) To examine bone mineral density in patients with treated adrenal insufficiency and examined the effect of hydrocortisone dose on bone mineral density. 29 
Cross sectional
Number of Crisis
The class of adrenocortical hormone replacement contributed "a little" to the occurrence of adrenal crisis. Study did not mention the doses of the adrenocortical replacement.
Rushworth
(34)
To study the morbidity pattern of adrenal insufficiency in Australia between 1999/2000 and 2011/2012
Patients with AI in Australia who were admitted for AC or other adrenal insufficiency causes during the period of the study (total number: 7378 admissions)
Cohort retrospective
Number of admissions for adrenal crisis
Increased rate of hospitalizations for adrenal crisis during the study period could be associated with increased use of hydrocortisone that is probably given at lower doses than in the past.
